341291 Sigma-AldrichFas/FasL Antagonist, Kp7-6 - Calbiochem
The Fas/FasL Antagonist, Kp7-6 controls the biological activity of Fas/FasL. This small molecule/inhibitor is primarily used for Cancer applications.
More>> The Fas/FasL Antagonist, Kp7-6 controls the biological activity of Fas/FasL. This small molecule/inhibitor is primarily used for Cancer applications. Less<<Fas/FasL Antagonist, Kp7-6 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
Synonyms: H-YC*DEHFC*Y-OH, Cyclic [Cys-Cys disulfide], Kp7-6
Recommended Products
Overview
| Replacement Information |
|---|
Key Spec Table
| Empirical Formula |
|---|
| C₄₈H₅₆N₁₀O₁₅S₂ |
Products
| Catalogue Number | Packaging | Qty/Pack | |
|---|---|---|---|
| 341291-25MGCN | 塑膠安瓿;塑膠針藥瓶 | 25 mg |
| Description | |
|---|---|
| Overview | An exocyclic cystine-knot peptide that specifically antagonizes Fas/FasL-mediated cellular apoptotic signals (58% reduction of FasL-induced apoptosis in Jurkat cells at 1 mg/ml). Binds to FasL (Cat. Nos. PF033 and PF092) and Fas (CD95/APO-1) with comparable affinity (Kd = 11.2 & 13.2 µM, respectively), resulting in disabled receptor ensembles and altered signaling pathways. Shown to prevent Con A (Cat. No. 234567)-induced liver injury in a murine hepatitis model in vivo. Does not bind to TNF-α or TNFR. |
| Catalogue Number | 341291 |
| Brand Family | Calbiochem® |
| Synonyms | H-YC*DEHFC*Y-OH, Cyclic [Cys-Cys disulfide], Kp7-6 |
| References | |
|---|---|
| References | Carmona, E.M., et al. 2006. J. Immunol. 177, 459. Hasegawa, A., et al. 2004. Proc. Natl. Acad. Sci. USA 101, 6599. |
| Product Information | |
|---|---|
| ATP Competitive | N |
| Declaration | Sold under license of U.S. Patent 7,288,519. |
| Form | White lyophilized powder |
| Formulation | Supplied as a trifluoroacetate salt. |
| Hill Formula | C₄₈H₅₆N₁₀O₁₅S₂ |
| Chemical formula | C₄₈H₅₆N₁₀O₁₅S₂ |
| Hygroscopic | Hygroscopic |
| Reversible | N |
| Quality Level | MQ100 |
| Applications |
|---|
| Biological Information | |
|---|---|
| Primary Target | Fas/FasL-mediated cellular apoptotic signals |
| Primary Target IC<sub>50</sub> | Kd = 11.2 & 13.2 µM for FasL and Fas (CD95/APO-1), respectively |
| Purity | ≥98% by HPLC |
| Physicochemical Information | |
|---|---|
| Cell permeable | N |
| Peptide Sequence | H₂N-Tyr-Cys*-Asp-Glu-His-Phe-Cys*-Tyr-CO₂H, Cyclic [disulfide bond between Cys-Cys] |
| Dimensions |
|---|
| Materials Information |
|---|
| Toxicological Information |
|---|
| Safety Information according to GHS |
|---|
| Safety Information |
|---|
| Product Usage Statements |
|---|
| Packaging Information | |
|---|---|
| Packaged under inert gas | Packaged under inert gas |
| Transport Information |
|---|
| Supplemental Information |
|---|
| Specifications |
|---|
| Global Trade Item Number | |
|---|---|
| Catalogue Number | GTIN |
| 341291-25MGCN | 04055977215618 |
Documentation
Fas/FasL Antagonist, Kp7-6 - Calbiochem MSDS
| Title |
|---|
Fas/FasL Antagonist, Kp7-6 - Calbiochem Certificates of Analysis
| Title | Lot Number |
|---|---|
| 341291 |
References
| Reference overview |
|---|
| Carmona, E.M., et al. 2006. J. Immunol. 177, 459. Hasegawa, A., et al. 2004. Proc. Natl. Acad. Sci. USA 101, 6599. |